Abstract: The cationic iridium carbene complexes [Ir(cod)(N)(L)]X have been synthesized by reaction of [Ir(cod)(py)2]PF6 with L or NL ligands. Complexes of this type are active hydrogenation catalysts capable of hydrogenating simple olefins at room temperature and atmospheric pressure of hydrogen or by transfer hydrogenation.

Abstract: In one aspect, the invention encompasses a semiconductor processing method of forming a metal-comprising layer over a substrate. A substrate is provided within a reaction chamber, and a source of a metal-comprising precursor is provided external to the reaction chamber. The metal-comprising precursor comprises a metal coordinated with at least one Lewis base to form a complex having a stoichiometric ratio of the at least one Lewis base to the metal. An amount of the at least one Lewis base is distributed within the source to an amount that is in excess of the stoichiometric ratio. At least some of the metal-comprising precursor is transported from the source to the reaction chamber. A metal is deposited from the metal-comprising precursor and onto the substrate within the reaction chamber. In another aspect, the invention encompasses a method of storing a metal-comprising material. A metal-comprising material is dispersed within a solution.

Abstract: Various olefins may be polymerized using a catalyst systems containing selected &agr;-diimine, urethane or urea ligands, some of them novel, complexed to nickel, palladium or other selected transition metals. The polymers are useful as molding resins and elastomers.

Abstract: The present invention is directed to a process for the production of monoalkylin trihalides of the formula RSnX3 wherein R-alkyl or cycloalkyl and X—Cl, Br or I involving a redistribution reaction between tetraorganotins, triorganotin halides or diorganotin halides and tin tetrahalides, said process comprising contacting tetra-(R4Sn), tri-(R3SnX) or diorganotin halides (R2SnX2) with SnX4 to afford said monoorganotin trihalides in the presence of at least one transition metal complex, said complex comprising at least one transition metal M, selected from Group VIII of the periodic Table of elements, at least one monodentate ligand or bidentate ligand, L, L′, or L″, and optionally one or more anions, X, of an organic or inorganic acid, as a catalyst or catalyst precursor.

Abstract: The invention concerns olefin polymerization catalyst component comprising an organometallic compound of general formula I wherein: M is a transition metal of groups 3, 4-10, lanthanide or actinide of the periodic table of the elements; each R is independently a structural bridge rigidly connecting two ligands L1, L2 and L3 and is constituted by 1 to 4 chain atoms selected from carbon, silicon, germanium, oxygen, boron; m, n and o are 0 or 1, with the proviso that m+n+o is 2 or 3; L1 is a ligand of the cyclopentadienyl type or is isolobal to cyclopentadienyl, L2 is a ligand of the cyclopentadienyl type or is isolobal to cyclopentadienyl, or a monovalent anionic ligand selected from the group consisting of N, P, B when m+n=2, it is selected from the group consisting of NR1, PR1, BR1, O and S when m+n=1; L3 is a monovalent anionic ligand selected from the group consisting of N, P, B when n+o=2, it is selected from the group consisting of NR1, PR1

Abstract: Compounds which may be used in the treatment and/or prevention of cancer have the formula (I) wherein: R1, R2, R3, R4, R5 and R6 independently represents H, alkyl, —CO2R′, aryl or akylaryl, which latter two groups are optionally substituted on the aromatic ring; R′ represent alkyl, aryl or alkaryl; X is halo, H2O, (R′)(R″)SO, R′CO2— or (R′)(R″)C═O, where R″ represents alkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C′ is C1 to C12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently N-donor nitrile ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR7R8 and B is NR9R10, wherein R7, R8, R9 and R10 independently represent H or alkyl, and A and B are linked by an alkylene chain, optionally s

Abstract: A class of anionic and neutral complexes of ruthenium (II) containing nitrogen oxide (NO) and optionally a nitrogen ligand is described; a process for their preparation is also described. The preparation process includes the use of starting complexes of ruthenium (III) which are reacted with suitable reagents so as to obtain complexes containing NO coordinated to ruthenium (II). Additional substitution reactions allow the introduction of new groups that coordinate to the ruthenium atom, among which some nitrogen ligands.

Abstract: This invention provides raw material compounds for use in CVD which contain organic ruthenium compounds as a main ingredient, the organic ruthenium compounds having two &bgr;-diketones plus one diene, one diamine or two organic ligands which are coordinated with ruthenium. In this invention, the vapor pressures of the organic ruthenium compounds are made preferable by specifying the number of the carbon atoms contained in the above &bgr;-diketones and the types of the above diene etc.

Abstract: The present invention describes platinum (II) compounds and compositions useful for treating a subject with a tumor and/or inducing apoptosis in a population of cells. The present invention also describes pharmaceutical compositions containing the aforementioned inventive compound(s) in combination with a pharmaceutically acceptable carrier. Additionally, the invention further provides a method of inducing apoptosis in a population of cells and a method of treating a subject with a tumor, wherein the method comprises administering to the subject a therapeutically effective amount of the aforementioned compound(s) or composition(s).

Abstract: Amines having an unsaturated bond can be introduced into the organic layer of organic-inorganic laminar perovskite compounds comprising a metal halide and an organic amine, and the organic layer can be polymerized by applying external energy such as by irradiating with UV light or radiation. In this way, the quantum well structure is stabilized. The organic-inorganic laminar perovskite polymer compound is produced by cross-linking unsaturated bonds of an organic-inorganic laminar perovskite compound represented by the general formula (RNH3)2MX4 (in the formula, R is a hydrocarbon group having an unsaturated bond, X is a halogen or mixture of same, M is Group IVa metal, Eu, Cd, Cu, Fe, Mn or Pd). R is represented by CH3(CH2)nC≡C—C≡CCH2 (n=2-14). It is preferred that M is Pb, and X is a bromine atom.

Abstract: Certain complexes containing ligands having a phosphino group, amino group or an imino group, and a second functional group such as amide, ester or ketone, when complexed to transition metals, catalyze the (co)polymerization of olefinic compounds such as ethylene, &agr;-olefins and/or acrylates. A newly recognized class of ligands for making copolymer containing polar monomers using late transition metal complexes is described.

Abstract: The present invention relates to an antitumor derivative of double dicarboxylic acid diaminoplatin complex of formula (I): wherein R1 and R2 have the meanings defined in the specification, also relates to a process for preparation thereof, to an antitumor pharmaceutical composition containing the same, and further to application of the derivative in making antitumor pharmaceutics. The composition is a new generation of safe and effective antitumor drug, which has advantages such as low toxicity, broad antitumor spectrum, high antitumor activity, good solubility in water and fine stability in aqueous solution, selective killing of cancer cells without damaging normal cells, etc.

Abstract: This invention discloses a series of dynamic platinum compounds and method of treating cancer by administering said compound to a cancer patient.

Abstract: Methods and compositions for the generation of polypeptides having varied material properties are disclosed herein. Methods include means for initiating the polymerization of aminoacid-N-carboxyanhydride (NCA) monomer by combining the monomer with an amido-containing metallacycle, for making self assembling amphiphilic block copolypeptides and related protocols for adding oligo(ethyleneglycol) functionalized aminoacid-N-carboxyanhydrides (NCAs) to polyaminoacid chains. Additional methods include means of adding an end group to the carboxy terminus of a polyaminoacid chain by reacting an alloc-protected amino acid amide with a transition metal-donor ligand complex to forming an amido-amidate metallacycle for use in further polymerization reactions. Novel compositions for use in peptide synthesis and design including five and six membered amido-containing metallacycles and block copolypeptides are also disclosed.

Abstract: Methods and compositions for the generation of polypeptides having varied material properties are disclosed herein. Methods include means for making block copolypeptides and related protocols for adding aminoacid-N-carboxyanhydrides (NCAs) to polyaminoacid chains by exposing the NCA to solutions containing polyaminoacid chains having an amido amidate metallacyle end groups and reacting the NCA with the amido containing metallacyle end group so that the NCA is added to the polyaminoacid chain. Addition methods include means of controlling the addition of aminoacid-N-carboxyanhydrides to polyaminoacid chains by reacting NCAs with initiator molecules and allowing initiator complexes to open the ring of the NCAs through oxidative addition across either the O—C5 or O—C2 anhydride bond resulting a controlled polypeptide polymerization. Novel compositions for use in peptide synthesis and design including five and six membered amido-containing metallacycles and block copolypeptides are also disclosed.

Abstract: One aspect of the present invention relates to novel ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in transition metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The subject methods provide improvements in many features of the transition metal-catalyzed reactions, including the range of suitable substrates, reaction conditions, and efficiency.

Abstract: An improved catalyst based on cobalt and/or rhodium dissolved in a non-aqueous ionic solvent which is liquid at a temperature of less than 90° C. More particularly, the catalyst comprises at least one complex of cobalt and/or rhodium co-ordinated with at least one nitrogen-containing ligand and the non-aqueous ionic solvent comprises at least one quaternary ammonium and/or phosphonium cation and at least one inorganic anion.

Abstract: The invention relates to a method for producing a mixture of alcohols/ketones by decomposing an alkyl hydroperoxide, particularly to a method for producing a cyclohexanol/cyclohexanone by decomposing cyclohexyl hydroperoxide in the presence of a heterogeneous catalyst. According to the invention, the reaction is carried out in the presence of a heterogeneous catalyst containing an organometallic segment fixed on the surface of a porous solid compound such as silicon. The organometallic segment can be formula (I).

Abstract: The present invention is generally directed to electroluminescent Ir(III) compounds, the substituted 2-phenylpyridines, phenylpyrimidines, and phenylquinolines that are used to make the Ir(III) compounds, and devices that are made with the Ir(III) compounds.

Abstract: A ruthenium complex represented by the following formula: RuL1L2X wherein L1 represents a 2,2′;6′,2″-terpyridine compound having at least one group selected from a carboxyl group, a salt of a carboxyl group, a sulfonic acid group, a salt of a sulfonic acid group, a phosphoric acid group and a salt of a phosphoric acid group, L2 represents a diketonate ligand represented by the following formula: wherein R1 and R2 are independently selected from alkyl, alkoxyalkyl, aminoalkyl, perfluoroalkyl and aryl, R3 represents a hydrogen atom, alkyl, alkoxyalkyl, aminoalkyl, perfluoroalkyl and aryl and X represents a monodentate ligand selected from a halide, a cyano group, a thiocyano group and a thiolate. A dye-sensitized oxide semiconductor electrode includes an electrically conductive body, an oxide semiconductor film provided on a surface of the electrically conductive body, and the above metal complex.

Abstract: Methods and compositions for the generation of polypeptides having varied material properties are disclosed herein. Methods include means for making self assembling amphiphilic block copolypeptides and related protocols adding oligo(ethyleneglycol) functionalized aninoacid-N-carboxyanhydrides (NCAs) to polyaminoacid chains. Additional methods include means of adding an end group to the carboxy terminus of a polyaminoacid chain by reacting an alloc-protected amino acid amide with a transition metal-donor ligand complex, thereby forming an amido-amidate metallacycle for use in further polymerization reactions. Novel compositions for use in peptide synthesis and design including five and six membered amido-containing metallacycles and block copolypeptides are also disclosed.

Abstract: The present invention describes platinum (II) compounds and compositions useful for treating a subject with a tumor and/or inducing apoptosis in a population of cells. The present invention also describes pharmaceutical compositions containing the aforementioned inventive compound(s) in combination with a pharmaceutically acceptable carrier. Additionally, the invention further provides a method of inducing apoptosis in a population of cells and a method of treating a subject with a tumor, wherein the method comprises administering to the subject a therapeutically effective amount of the aforementioned compound(s) or composition(s).

Abstract: The present invention relates to a molecular weight-enlarged, homogeneously soluble ligand, which includes: an average molecular weight of at least 1000 g/mol; a molecular weight-enlarging polymer; optionally, a linker; and at least one homochiral active center; wherein the active center is bound to the molecular weight-enlarging polymer through the linker or is bound directly to the molecular weight-enlarging polymer, methods of preparing, catalysts containing same, and methods of using same.

Abstract: Chelating ligand precursors for the preparation of olefin metathesis catalysts are disclosed. The resulting catalysts are air stable monomeric species capable of promoting various metathesis reactions efficiently, which can be recovered from the reaction mixture and reused. Internal olefin compounds, specifically beta-substituted styrenes, are used as ligand precursors. Compared to terminal olefin compounds such as unsubstituted styrenes, the beta-substituted styrenes are easier and less costly to prepare, and more stable since they are less prone to spontaneous polymerization. Methods of preparing chelating-carbene metathesis catalysts without the use of CuCl are disclosed. This eliminates the need for CuCl by replacing it with organic acids, mineral acids, mild oxidants or even water, resulting in high yields of Hoveyda-type metathesis catalysts.

Abstract: New derivatives of platinum (II) complex are herein provided, which are liposoluble and applicable as antimicrobial agents and anticancer agents specific to the affected parts of patients and selectively transferred to the parts if they are used in combination with a contrast medium such as lipiodol, the derivatives being represented by the following general formula: (wherein R1 and R2 may be identical or different with each other and represent an ammine optionally substituted with an organic substituent and they may be bonded together through a bivalent organic group and R3 is a saturated or unsaturated higher fatty acid, these derivatives being prepared by nitrifying a cis-dichloro-di-(substituted or unsubstituted)-ammine platinum (II) and then reacting the resulting aqua type product with a corresponding alkali metal salt of higher fatty acid.

Abstract: Nitrates of Bis-platinum complexes with polyamine ligands of formula (I) having antitumor activity and pharmaceutical compositions containing said compounds as active principles.

Abstract: Provided is a process for preparing an optically active ruthenium-phosphine complex represented by the following formula (1): wherein L represents a bidentate ligand compound of a tertiary phosphine; X represents a halogen atom; and * means chiral center (L* is an optically active substance), which comprises reacting a ruthenium-phosphine complex represented by: RumXnLpAq or [RuX(D)(L)]X wherein, X and L have the same meanings as described above (L is a racemic modification); A represents triethylamine (Et3N), etc.; and m, n, p and q each stands for an integer and D represents benzene, etc. with ½ equivalent of a specific optically active chiral diamine, thereby inactivating one of the enantiomers; and then with a specific optically active diamine derivative, thereby activating the other enantiomer.

Abstract: A process for preparing 1,2-diimine compounds of the formula I where R1 and R2 are, independently of one another, alkyl, aryl or metallocenyl radicals, and R3, R4 are, independently of one another, H, alkyl or aryl radicals or R3 and R4 are joined so as to form, with inclusion of the two imine carbon atoms, a 5- to 8-membered ring which may be saturated or unsaturated and may be unsubstituted or substituted by any hydrocarbon radicals. The process involves reacting 1,2-dicarbonyl compounds with primary amines, which have been activated with trialkylaluminum compounds prior to the reaction with the 1,2-dicarbonyl compounds. 1,2-Diimine compounds of the formula I in which R1 and R2 are, independently of one another, metallocenyl radicals can be used to prepare metal complexes which can be used as catalysts in a process for the polymerization of unsaturated compounds.

Abstract: The invention relates to novel transition metal complexes containing at least one diaminocarbene ligand, to processes for preparing these transition metal complexes and to their use as catalysts in organic reactions.

Abstract: Pro-drug forms of linear polyamine-bridged platinum compounds and methods for their production and use are provided. The polyamine-bridge portion of the compounds is based on spermine or spermidine, and the central amines of the polyamine-bridge are chemically bonded to labile blocking groups. The presence of the blocking groups serves to minimize the toxicity of the Pt compounds upon administration. Selective removal of the blocking groups and release of the active, unblocked species occurs upon exposure to suitable environmental conditions.

Abstract: A process for producing a ring-substituted arene borane which comprises reacting a ring-substituted arene with an HB organic compound in the presence of a catalytically effective amount of an iridium or rhodium complex with three or more substituents, excluding hydrogen, bonded to the iridium or rhodium and a phosphorus organic ligand, which is at least in part bonded to the iridium or rhodium, to form the ring-substituted arene borane. Also provided are catalytic compounds for catalyzing the process comprising an iridium or rhodium complex with three or substituents, excluding hydrogen, bonded to the iridium or rhodium and optionally, a phosphorus organic ligand, which is at least in part bonded to the iridium or rhodium.

Abstract: There is provided a method of synthesis of a radiolabelled platinum chemotherapeutic agent comprising the steps of: converting a metal halide to a radiolabelled platinum halide wherein the radiolabel is a radioisotope of Pt; and synthesising the radiolabelled platinum chemotherapeutic agent from the radiolabelled platinum halide.

Abstract: Methods for making Group VIII metal bis(imine) complexes are disclosed. Each method uses a single reactor that is equipped with an internal filter to facilitate preparation and purification of the complex under an inert atmosphere. The complexes, which are useful in catalyst systems for olefin polymerization, are prepared in either one or two reaction steps. Surprisingly, the single-reactor approach to preparation and purification enables the efficient preparation of exceptionally high (>90%) yields of desirable Group VIII metal bis(imine) complexes.

Abstract: An electroluminescence device having a layer containing a specific metal coordination compound is provided.

Abstract: Metal complexes obtainable from a metal precursor of a metal of the 6th-10th groups of the Periodic Table in the oxidation state 0 or +2 and a ligand of the formula I, where the radicals are defined as follows: R1, R2 and R4 are hydrogen, C1-C12-alkyl groups, C3-C12-cycloalkyl groups, C6-C14-aryl groups, C2-C12-alkenyl groups, arylalkyl groups, halogens, silyl groups, C1-C12-alkoxy groups, C1-C12-thioether groups or amino groups; R3 is an &agr;-branched C3-C12-alkyl group or a substituted or unsubstituted C3-C12-cycloalkyl group, a C2-C12-alkenyl group, an arylalkyl group, a halogen, a silyl group, a C1-C12-alkoxy group, a C1-C12-thioether group or an amino group; X is oxygen, sulfur, Y is hydrogen or a silyl group, R5 to R6 are &agr;-branched C3-C12-alkyl groups or substituted or unsubstituted C3-C12-cycloalkyl groups; can be used in free form or immobilized on a solid support for the polymerization of 1-olefins.

Abstract: The synthesis and the use of a series of carboplatin analogs is disclosed. These carboplatin analogs may be represented by cis-Pt(II)L1L2, wherein each of L1 and L2, independently, is the carboxylate of phosphatidylserine, an &agr;-amino acid, a &bgr;-amino acid, or a derivative thereof, wherein each ligand is bidentate with —NH2 and —COO− as the binding sites. The complexes can be used in the treatment of cancer.

Abstract: The invention relates to a method for differentially labelling one or more entities, together comprising distinct reactive sites. The invention further relates to an entity that has been labelled by a method according to the invention and to a diagnostic kit comprising a labelled entity and to a diagnostic kit to employ a method according to the invention.

Abstract: Chiral ligands and transition metal complexes based on such chiral ligands useful in asymmetric catalysis are disclosed. The chiral ligands include chiral C1-C6 TunaPhos ligands. The ruthenium TunaPhos complex reduces ketones to the corresponding alcohols with 95-99.6% enantioselectivity. The transition metal complexes of the chiral ligands are useful in asymmetric reactions such as asymmetric hydrogenation, hydride transfer, hydrosilylation, hydroboration, hydrovinylation, hydroformylation, hydrocarboxylation, isomerization, allylic alkylation, cyclopropanation, Diels-Alder reaction, Heck reaction, isomerization, Aldol reaction, Michael addition and epoxidation reactions.

Abstract: The present invention relates to the area of platinum drugs.

Abstract: Ruthenium and osmium carbene compounds that are stable in the presence of a variety of functional groups and can be used to catalyze olefin metathesis reactions on unstrained cyclic and acyclic olefins are disclosed. Also disclosed are methods of making the carbene compounds. The carbene compounds are of the formula where M is Os or Ru; R1 is hydrogen; R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, and substituted or unsubstituted aryl; X and X1 are independently selected from any anionic ligand; and L and L1 are independently selected from any neutral electron donor. The ruthenium and osmium carbene compounds of the present invention may be synthesized using diazo compounds, by neutral electron donor ligand exchange, by cross metathesis, using acetylene, using cumulated olefins, and in a one-pot method using diazo compounds and neutral electron donors.

Abstract: The invention provides a metal complex comprising a ligand and a metal. The ligand is an aminophosphine compound represented by the following formula (1) [Each Ar represents an aryl group optionally substituted with a halogen atom, a lower alkyl group having 1 to 4 carbon atom or an alkoxy group, both Ar's being same or different with each other. R1 and R2 represent hydrogen atom, a cycloalkyl group having 5 to 7 carbon atoms, or an alkyl group having 1 to 6 carbon atom optionally substituted with a halogen atom, a lower alkoxy group or phenyl group, with R1 and R2 being same or different with each other.

Abstract: The present invention relates to catalyst systems, processes for making such catalysts, intermediates for such catalysts, and olefin polymerization processes using such catalysts wherein such catalyst includes a component represented by the following formula 1A: wherein R and R′ independently represent a hydrogen atom, or a substituted or unsubstituted, branched or unbranched hydrocarbyl or organosilyl radical; R1, R2, and R3 independently represent a hydrogen atom, or a substituted or unsubstituted, branched or unbranched hydrocarbyl radical; M is a group IIIB, IVB, VB, VIB, VIIB or VIII transition metal; T independently represents a univalent anionic ligand such as a hydrogen atom, or a substituted or unsubstituted hydrocarbyl halogeno, aryloxido, arylorganosilyl, alkyloriganosilyl, amido, arylamido, phosphido, or arylphosphido group, or two T groups taken together represent an alkylidene or a cyclometallated hydrocarbyl bidentate ligand; L independently represents a sigma donor

Abstract: Laundry detergents and cleaners which, in addition to a peroxide compound, comprise a compound of the formula (R1R1)N—X—N(R1R1)  (I) or metal complexes thereof, where X and R1 have the meanings listed in the description, are claimed.

Abstract: Disclosed is a platinum complex of formula (I) wherein X represents a halogen atom, B represent, independently to each other, a halogen atom, a hydroxyl group or a carboxylate group containing 1 to 6 carbon atoms, and A represents a croup —NH2—R wherein R is a tricyclic hydrocarbon moiety containing 10 to 14 carbon atoms which may be optionally substituted on the tricyclic ring by one or two alkyl group(s) each containing 1 to 4 carbon atoms, and, furthermore, an inclusion complex of the above platinum complex with beta- or gamma-cyclodextrin which may be optionally substituted by hydroxyalkyl groups containing 1 to 6 carbon atoms. There is also disclosed a process for the manufacture of the complex of formula (I) based on oxidation of a complex of divalent platinum of formula (II) with hydrogen peroxide and on optional substitution of hydroxyl groups in the obtained product with carboxylate groups by action of an acylating agent.

Abstract: The present invention is concerned with novel processes for the preparation of (R)-1-(3,5-bis(trifluoromethyl)phenyl)ethan-1-ol. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.

Abstract: Cationic ruthenium complexes of the formula A or B or mixtures containing them, where B may be stabilized by a further ligand L4 and X is an anion which does not coordinate or coordinates weakly to the metal center, Y is a monodentate or multidentate anionic ligand, R and R′ are each, independently of one another, hydrogen or a substituted or unsubstituted C1-C20-alkyl, C6-C20-aryl or C7-C20-alkylaryl radical and L1, L2, L3 and L4 are, independently of one another, uncharged electron donor ligands, are described.

Abstract: The present invention concerns novel complexes, suitable in particular for use as catalysts in the asymmetric hydrogenation of ketones, of formula 1 or a diastereoisomer thereof, wherein each Ar is an aromatic or heteroaromatic group of up to 20 atoms; X is halide or carboxylate; and R1, R2, R3, and R4 are independently hydrogen, aryl or alkyl, optionally linked or part of a ring.

Abstract: The cationic iridium carbene complexes [Ir(cod)(N)(L)]X have been synthesized by reaction of [Ir(cod)(py)2]PF6 with L or NL ligands. Complexes of this type are active hydrogenation catalysts capable of hydrogenating simple olefins at room temperature and atmospheric pressure of hydrogen or by transfer hydrogenation.

Abstract: The invention relates to novel platinum-based compounds for labeling biomolecules. Platinum based labeling compounds according to the invention irreversibly attach to a target biomolecule via coordination of a platinum (II) metal center with N or S atoms on the target biomolecule. The invention relates to the novel compounds themselves, methods of making the platinum-based labeling compounds, probes labeled with such compounds, methods of making such labeled probes, and kits comprising the novel platinum-based labeling compounds and/or probes labeled with them. The invention also relates to methods of using probes labeled with platinum-based labeling compounds of the invention, particularly array and microarray hybridization methods.

Abstract: A process for synthesizing complexes of platinum(II) with iminoethers having the formula: [PtIIX2(L)(L′)], where X is a monoanionic ligand, L is an iminoether ligand and L′ is an amine group or, exclusively for the case of cyclic iminoethers, a second iminoether ligand. The platinum(II) complexes according to the present invention are suitable for the production of medical remedies having a broad antitumoral spectrum. The complexes of platinum(II) with iminoethers according to the invention are furthermore suitable as agents for modifying nucleotide bases into antisense and/or antigene oligonucleotides.